Literature DB >> 7635853

Major depression and irritable bowel syndrome: is there a relationship?

P S Masand1, D S Kaplan, S Gupta, A N Bhandary, G S Nasra, M D Kline, K L Margo.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) has been reported in 10% to 22% of adults. Seventy percent to 90% of patients with IBS who seek medical attention have psychiatric comorbidity, most commonly major depression. In contrast, few studies have looked at the prevalence of IBS among psychiatric patients.
METHOD: Using a semistructured clinical interview to study the prevalence of IBS, we compared 56 patients seeking treatment for major depression in an outpatient setting to an age- and sex-matched control group of patients (N = 40) who were seeking treatment in a general physician's office for other medical illnesses. The control group had no Axis I disorders. IBS was diagnosed according to the criteria of Drossman et al.
RESULTS: Twenty-seven percent (N = 15) of patients with major depression met criteria for IBS in contrast to 2.5% (N = 1) of the control group (p = .0005). Patients with major depression and IBS were more likely to report symptoms of back pain, weakness, heartburn, and nocturnal bowel movements as well as a personal or family history of bowel disease compared with patients with major depression but without IBS.
CONCLUSION: IBS is fairly common in patients seeking treatment for major depression. Prospective studies should address the question whether treatment of major depression leads to an improvement or resolution of the symptoms of IBS.

Entities:  

Mesh:

Year:  1995        PMID: 7635853

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  26 in total

Review 1.  Irritable bowel syndrome.

Authors:  S M Turner; J E Stewart; J J Alexopulos; J S Hill
Journal:  Curr Rev Pain       Date:  2000

2.  Family history of mental illness or alcohol abuse and the irritable bowel syndrome.

Authors:  James R Knight; G Richard Locke; Alan R Zinsmeister; Cathy D Schleck; Nicholas J Talley
Journal:  J Psychosom Res       Date:  2014-12-03       Impact factor: 3.006

3.  Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study.

Authors:  Prakash S Masand; Sanjay Gupta; Thomas L Schwartz; Subhdeep Virk; Ahmad Hameed; David S Kaplan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

4.  Intestinal transit in anxiety and depression.

Authors:  D A Gorard; J E Gomborone; G W Libby; M J Farthing
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

5.  A Structural Equation Model of HIV-related Symptoms, Depressive Symptoms, and Medication Adherence.

Authors:  Moka Yoo-Jeong; Drenna Waldrop-Valverde; Katryna McCoy; Raymond L Ownby
Journal:  J HIV AIDS       Date:  2016-04-06

Review 6.  The interface of psychiatry and irritable bowel syndrome.

Authors:  David G Folks
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

7.  Prevalence of irritable bowel syndrome: a community survey.

Authors:  Sue Wilson; Lesley Roberts; Andrea Roalfe; Pam Bridge; Sukhdev Singh
Journal:  Br J Gen Pract       Date:  2004-07       Impact factor: 5.386

8.  Relationship of lifestyle and clinical factors to lower urinary tract symptoms: results from Boston Area Community Health survey.

Authors:  Heather J Litman; William D Steers; John T Wei; Varant Kupelian; Carol L Link; John B McKinlay
Journal:  Urology       Date:  2007-10-24       Impact factor: 2.649

9.  Paroxetine in Patients With Irritable Bowel Syndrome: A Pilot Open-Label Study.

Authors:  Prakash S. Masand; Sanjay Gupta; Thomas L. Schwartz; Subhdeep Virk; Kari Lockwood; Ahmad Hameed; Monica King; David S. Kaplan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-02

10.  Psychopathology in irritable bowel syndrome: support for a psychophysiological model.

Authors:  Mark A Sykes; Edward B Blanchard; Jeffery Lackner; Laurie Keefer; Susan Krasner
Journal:  J Behav Med       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.